Skip to main content
SpringerLink
Log in

Antithrombotic Therapy for Stroke Prevention in Patients With Heart Failure

  • Cerebrovascular Disease and Stroke (M Alberts and C Helgason, Section Editors)
  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

Congestive heart failure (CHF) is associated with an increased risk of stroke mainly due stasis leading to increased risk of thrombus formation in the left ventricle and subsequent cerebral embolism. CHF patients are also at increased risk of atrial fibrillation (AF) that also leads to cerebral embolism. Aggressive medical management to prevent cardiac decompensation and maintain sinus rhythm is indicated in CHF patients. All patients with CHF and AF should be anticoagulated with warfarin or one of the newer oral anticoagulants. There is no clear indication for anticoagulation in CHF patients due to ischemic cardiomyopathy who are in sinus rhythm. Based on data from the WARCEF study (see below), those patients with CHF due to non-ischemic etiologies who are in sinus rhythm and have a left ventricular ejection fraction (LVEF) less than 30 % to 35 % may benefit from warfarin for the reduction of ischemic stroke risk, but warfarin does not increase survival. Whether warfarin is particularly beneficial for CHF patients who have a prior history of stroke or transient ischemic attack (TIA) is unknown. If, however, there is high enough suspicion that the stroke was of cardioembolic origin in patients with low LVEF, then anticoagulation would possibly be a reasonable option for prevention of recurrent stroke or TIA. Warfarin is indicated for stroke prophylaxis among those CHF patients who have an implanted mechanical device. The role of newer anticoagulants in patients with CHF who do not have AF is unknown at this time. Theoretically, there should be no reason against using these agents in place of warfarin in selected patients, particularly those with highly variable International Normalized Ratios (INR) in the context of warfarin therapy, but the newer anticoagulants have not yet been studied among CHF patients without concomitant AF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, et al. Heart Disease and Stroke Statistics 2011. A report from the American Heart Association. Circulation. 2011;123:e18–e209.

    Article  PubMed  Google Scholar 

  2. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123(8):933–44.

    Article  PubMed  Google Scholar 

  3. Wolf PA, Kannel WB, McNamara PM. Occult impaired cardiac function, congestive HEART FAILURE, and risk of thrombotic stroke the Framingham Study. Neurology. 1970;20:373.

    Article  PubMed  CAS  Google Scholar 

  4. Wolf PA, D’Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991;22(3):312–8.

    Article  PubMed  CAS  Google Scholar 

  5. Appelros P. Heart failure and stroke. Stroke. 2006;37(7):1637.

    Article  PubMed  Google Scholar 

  6. Snowden S, Silus L. Oral anticoagulation with warfarin for patients with left ventricular systolic dysfunction. Cardiol Rev. 2011;19(1):36–40.

    Article  PubMed  Google Scholar 

  7. Hays AG, Sacco RL, Rundek T, Sciacca RR, Jin Z, Liu R, et al. Left ventricular systolic dysfunction and the risk of ischemic stroke in a multiethnic population. Stroke. 2006;37:1715–9.

    Article  PubMed  Google Scholar 

  8. Loh E, Sutton MS, Wun CC, Rouleau JL, Flaker GC, et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med. 1997;336(4):251–7.

    Article  PubMed  CAS  Google Scholar 

  9. Sharma ND, McCullough PA, Philbin EF, Weaver WD. Left ventricular thrombus and subsequent thromboembolism in patients with severe systolic dysfunction. Chest. 2000;117(2):314–20.

    Article  PubMed  CAS  Google Scholar 

  10. Chong AY, Blann AD, Patel J, Freestone B, Hughes E, Lip GYH. Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated dilation to circulating endothelial cells. Plasma indexes of endothelial damage and brain natriuretic peptide. Circulation. 2004;1110:1794–8.

    Article  Google Scholar 

  11. Jafri SM, Ozawa T, Mammen E, Levine TB, Johnson C, Goldstein S. Platelet function, thrombin and fibrinolytic activity in patients with heart failure. Eur Heart J. 1993;14(2):205–12.

    Article  PubMed  CAS  Google Scholar 

  12. Pullicino PM, McClure LA, Wadley VG, Ahmed A, Howard VJ, Howard G, et al. Blood pressure and stroke in heart failure in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. Stroke. 2009;40(12):3706–10.

    Article  PubMed  Google Scholar 

  13. Witt BJ, Brown Jr RD, Jacobsen SJ, Weston SA, Ballman KV, Meverden RA, et al. Ischemic stroke after HEART FAILURE: a community-based study. Am Heart J. 2006;152(1):102–9.

    Article  PubMed  Google Scholar 

  14. Alberts VP, Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, Stricker BH, et al. Heart failure and the risk of stroke: the Rotterdam Study. Eur J Epidemiol. 2010;25(11):807–12.

    Article  PubMed  CAS  Google Scholar 

  15. Cugno M, Mari D, Meroni PL, Gronda E, Vicari F, et al. Haemostatic and inflammatory biomarkers in advanced chronic heart failure: role of oral anticoagulants and successful heart transplantation. Br J Haematol. 2004;126(1):85–92.

    Article  PubMed  CAS  Google Scholar 

  16. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. J Am Coll Cardiol. 2006;48(4):e149–246.

    Article  Google Scholar 

  17. Wann LS, Curtis AB, Ellenbogen KA, Lowe JE, Estes III M, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline). Circulation. 2011;123:104–23.

    Article  PubMed  Google Scholar 

  18. Massie BM, Collins JF, Ammon SE, Armstrong PW, Cleland JG, Ezekowitz M, et al. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic HEART FAILURE: the Warfarin and Antiplatelet Therapy in Chronic HEART FAILURE (WATCH) trial. Circulation. 2009;119(12):1616–24.

    Article  PubMed  CAS  Google Scholar 

  19. Cokkinos DV, Haralabopoulos GC, Kostis JB, Toutouzas PK, HELAS Investigators. Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. Eur J Heart Fail. 2006;8(4):428–32.

    Article  PubMed  CAS  Google Scholar 

  20. Pullicino P, Thompson JL, Barton B, Levin B, Graham S, Freudenberger RS. Warfarin versus aspirin in patients with reduced cardiac ejection fraction (WARCEF): rationale, objectives, and design. J Card Fail. 2006;12(1):39–46.

    Article  PubMed  CAS  Google Scholar 

  21. Homma S, Thompson JLP for the WARCEF Investigators. Results of the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial. International Stroke Conference 2012; Late Breaking Abstract 12. New Orleans, Louisiana. This study raises many questions. Although it did not show superiority of warfarin and aspirin in reducing death, ischemic stroke, and ICH, warfarin was superior than aspirin in reducing the rate of ischemic stroke and the ICH rate was low. Further studies, perhaps using newer oral anticoagulants, may be indicated.

  22. Gage BF, Birman-Deych E, Radford MJ, Nilasena DS, Binder EF. Risk of osteoporotic fracture in elderly patients taking warfarin. Results from the National Registry of Atrial Fibrillation 2. Arch Intern Med. 2006;166(2):241–6.

    Article  PubMed  CAS  Google Scholar 

  23. Lip GYH, Chung I. Anticoagulation for heart failure in sinus rhythm. Cochrane Database of Systematic Reveiws 2001. Issue 4 Art No CD003336 doi:10.1002/14651858. Assessed as up to date: December 1, 2005

  24. Sorensen SV, Dewilde S, Singer DE, Goldhaber SZ, Monz BU, Plumb JM. Cost-effectiveness of warfarin: trial versus “real-world” stroke prevention in atrial fibrillation. Am Heart J. 2009;157(6):1064–73.

    Article  PubMed  Google Scholar 

  25. Schneck MJ. Understanding the PRoFESS study for secondary stroke prevention. Curr Treat Options Cardiovasc Med. 2009;11(3):221–31.

    Article  PubMed  Google Scholar 

  26. The ACTIVE Writing Group. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367:1903–12.

    Article  Google Scholar 

  27. The ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360:2066–78.

    Article  Google Scholar 

  28. Desai AS, Healey JS, Pfeffer MA, et al.; for the ACTIVE Investigators. Aspirin and the risk of HF hospitalization in patients with atrial fibrillation and a prior history of HEART FAILURE: an ACTIVE-W analysis. Presented at the 10th Annual Scientific Meeting of the HEART FAILURE Society of America; September 10–13, 2006; Seattle, Washington.

  29. Morales-Vidal S, Schneck MJ, Flaster M, Biller J. Direct thrombin inhibitors and factor Xa inhibtors in patients with cerebrovascular disease. Expert Rev Neurorther 12(2) February 2012.

  30. Connoly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldfren J, for the Re-Ly Investigators, et al. Dabigatran versus Warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.

    Article  Google Scholar 

  31. Eerenberg ES, Kamhuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized placeb0-controlled crossover study in health subjects. Circulation (online publication September 2011).

  32. Freeman JV, Zhu RP, Owens DK, et al. Cost-effective of dabigatran compared ith warfarin for stroke prevention in atrial fibrillation. Ann Int Med. 154(1):1–11

  33. Patel MR, Mahaffey KW, Garg J, for the ROCKET AF Investigators, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.

    Article  PubMed  CAS  Google Scholar 

  34. Gheorghiade M, Thyssen A, Zolynas R, Nadar VK, Greenberg BH, et al. Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic HEART FAILURE. J Heart Lung Transplant. 2011;30:218–26.

    Article  PubMed  Google Scholar 

  35. Connoly SJ, Eikelboom J, Joyner C, Diener H-C, Hart R, for the AVERROES Investigators, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806–17.

    Article  Google Scholar 

  36. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, for the ARISTOTLE Committees and Investigators, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

No conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Department of Neurology, Loyola University Medical Center, Maguire Building, Suite 2700, 2160 South First Avenue, Maywood, IL, 6015, USA

    David Hyman BA, Sarkis Morales-Vidal MD & Michael J. Schneck MD

Authors
  1. David Hyman BA
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sarkis Morales-Vidal MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael J. Schneck MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael J. Schneck MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hyman, D., Morales-Vidal, S. & Schneck, M.J. Antithrombotic Therapy for Stroke Prevention in Patients With Heart Failure. Curr Treat Options Cardio Med 14, 215–226 (2012). https://doi.org/10.1007/s11936-012-0177-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-012-0177-6

Keywords

Search

Navigation